C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 120 filers reported holding C4 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,630 | -39.9% | 14,855 | -11.2% | 0.00% | – |
| Q2 2023 | $46,008 | -4.5% | 16,730 | +9.0% | 0.00% | – |
| Q1 2023 | $48,174 | -62.9% | 15,342 | +3.5% | 0.00% | -100.0% |
| Q3 2022 | $130,000 | +16.1% | 14,822 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $112,000 | -68.9% | 14,822 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $360,000 | -43.4% | 14,822 | -25.0% | 0.00% | -50.0% |
| Q4 2021 | $636,000 | -46.0% | 19,762 | -25.0% | 0.00% | -60.0% |
| Q3 2021 | $1,177,000 | +18.1% | 26,349 | 0.0% | 0.01% | +11.1% |
| Q2 2021 | $997,000 | +24825.0% | 26,349 | +24297.2% | 0.01% | – |
| Q1 2021 | $4,000 | – | 108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |